

December 10, 2025



# Kane Biotech Receives Health Canada Approval for revyve® Antimicrobial Wound Gel Spray

WINNIPEG, Manitoba, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) ("Kane Biotech", "Kane" or the "Company") today announces that Health Canada has approved its revyve® Antimicrobial Wound Gel Spray for use in Canada.



## *Health Canada approved revyve Antimicrobial Wound Gel Spray*

revyve Antimicrobial Wound Gel Spray has been previously cleared under the FDA 510(k) process. This Health Canada approval represents another regulatory milestone for Kane and the Company's commitment to advancing wound care innovation in Canada. The revyve Antimicrobial Wound Gel Spray is designed to support clinicians in managing complex wounds by helping to reduce microbial burden and promote a healthier wound environment.

Health Canada approval provides clinicians and patients in Canada with access to a new wound care option for managing burns, large surface area wounds and ulcers. The spray is part of Kane Biotech's revyve wound care portfolio, which has been evaluated in multiple clinical settings in the United States.

Dr. Robert B. Huizinga, Interim CEO of Kane Biotech, commented, "Health Canada's approval of the revyve Antimicrobial Wound Gel Spray is another step forward in our mission to improve outcomes for patients with chronic and hard-to-heal wounds. This approval validates the strength of our clinical data and provides Canadian healthcare providers with a new tool to address the burden of wound infections."

The Company will work closely with healthcare partners and distributors to ensure appropriate access and education around the use of revyve Antimicrobial Wound Gel Spray. Kane Biotech continues to advance its wound care portfolio, including the recent FDA submission of revyve Antimicrobial Wound and Skin Cleanser as the Company's third product in its revyve product line.

### **About Kane Biotech Inc. (TSX-V: KNE)**

Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve<sup>®</sup> addresses both biofilms and wound bacteria. revyve<sup>®</sup> Antimicrobial Wound Gel and revyve<sup>®</sup> Antimicrobial Wound Gel Spray are US FDA 510(k) cleared. revyve<sup>®</sup> Antimicrobial Wound Gel is Health Canada approved. To learn more about revyve, visit [revyvegel.com](http://revyvegel.com) or [revyvegel.ca](http://revyvegel.ca).

### **Join Kane's Distribution List & Social Media:**

To stay informed on the latest developments, sign-up for the Company's email distribution list [HERE](#).

### **Follow Kane**

**Website:** [kanebiotech.com](http://kanebiotech.com)

**LinkedIn:** <https://www.linkedin.com/company/kanebiotech/>

**Presentations:** <https://kanebiotech.com/publications-posters/>

**For more information:**

**Dr. Robert Huizinga**  
Interim CEO  
Kane Biotech Inc.  
[rhuizinga@kanebiotech.com](mailto:rhuizinga@kanebiotech.com)  
(780) 970-1100

**Ray Dupuis**  
Chief Financial Officer  
Kane Biotech Inc.  
[rdupuis@kanebiotech.com](mailto:rdupuis@kanebiotech.com)  
(204) 298-2200

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

**Caution Regarding Forward-Looking Information**

*This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company's: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at [www.sedar+.ca](http://www.sedar+.ca). The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.*

A photo accompanying this announcement is available at  
<https://www.globenewswire.com/NewsRoom/AttachmentNg/5d8b1ee8-17aa-461e-b855-8aa0088e8861>



Source: Kane Biotech Inc.

**Health Canada approved revyve Antimicrobial Wound Gel Spray**



Health Canada approved revyve Antimicrobial Wound Gel Spray